HeartSciences Bets Big on AI Amid Surging Heart Disease Deaths
For HeartSciences CEO Andrew Simpson, the pandemic’s fallout only underscores the urgent need for better cardiac diagnostic tools. HeartSciences Bets Big on AI Amid Surging Heart Disease Deaths In a
New study reveals HeartSciences’ MyoVista as a breakthrough in cardiac screening
© Provided by New York Tech In recent news, HeartSciences has made significant strides in the fight against heart disease among diabetic patients. Their groundbreaking AI-ECG device, MyoVista, has shown remarkable
HeartSciences Announces Podium Presentation at World Congress of Anesthesiologists on the Utility of MyoVista® Wavelet ECG For Detection of Left Ventricular Diastolic Dysfunction in Preoperative Patients
March 26, 2024 Data Demonstrated the Use of MyoVista wavECGTM for Screening Preoperative Patients for LVDD Can Be Recommended Southlake, Texas, March 26, 2024 (GLOBE NEWSWIRE) — Heart Test Laboratories, Inc. d/b/a
View All HeartSciences’ Announces Peer-Reviewed Publication Evaluating Use of MyoVista® Technology to Detect Asymptomatic Left Ventricular Dysfunction in Patients with Type 2 Diabetes
HeartSciences’ Announces Peer-Reviewed Publication Evaluating Use of MyoVista® Technology to Detect Asymptomatic Left Ventricular Dysfunction in Patients with Type 2 Diabetes March 12, 2024 Data Demonstrated MyoVista AI-ECG model significantly
View All HeartSciences Announces Canada Patent Grant Covering MyoVista® Wavelet Technology
March 6, 2024 Southlake, TX, March 06, 2024 (GLOBE NEWSWIRE) — Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (AI)-powered medical technology company focused
Today Show highlights that AI-ECG is set to change medicine and save lives.
Excerpt from the Today Show. Watch the video using the following link: heartsciences.com/wp-content/uploads/2024/02/The-cutting-edge-way-doctors-are-using-AI-to-save-lives_1.mp4